Featured Story | By Annalee Armstrong After watching Gilead and Roche dive deeper into TIGIT immunotherapies, Novartis is heading straight for the senior class. The Swiss pharma is getting in on the game via a blockbuster deal with BeiGene, which could ultimately net $1 billion for a late-stage asset. read more |
| |
|---|
|
| 
| Webinar: Improving the discovery of novel drugs with artificial intelligence Thursday, February 3, 2022 | 2pm ET / 11am PT This webinar will cover the newest and most innovative AI solutions that have been developed for the life sciences industry. Topics include how AI can be used to improve the ability to predict which compounds are likely to make it to late-stage trials, best practices for choosing and partnering with technology developers to maximize the benefits of AI in drug development, and more. Register now. |
Top Stories By Annalee Armstrong Since coming under the Roche banner in 2019, Spark Therapeutics has been working towards a massive expansion of its manufacturing capacity. Those efforts came to fruition Friday, and the companies intend to leave a few rooms open in the new $575 million facility for future growth. read more By Phil Taylor There are a number of potential blockbuster drugs on the list, but it’s not all about revenue potential. Many of the compounds are high-risk, high-reward candidates trying to push the boundaries of drug treatment. read more By Annalee Armstrong Roche’s Genentech has signed what could be a $720 million deal for Lineage Cell Therapeutics’ cell therapy for a range of eye disorders. Lineage is developing a retinal pigment epithelium cell therapy in dry age-related macular degeneration with geographic atrophy. read more By Nick Paul Taylor Novartis’ attempt to establish ligelizumab as the successor to its blockbuster Xolair has hit a roadblock. The new molecule failed to better the old stager in a phase 3 clinical trial, leaving Novartis uncertain of its next steps for the program. read more By Nick Paul Taylor Armgo Pharma is returning to its roots to deliver clinical proof of concept for its pipeline-in-a-product. After shifting focus from abnormal heart rhythm to neuromuscular disorders, Armgo is now returning to arrhythmias for its push into phase 2—and has armed itself with $35 million from Forbion and other VCs to go after the indication. read more By Kyle LaHucik Researchers say they have found a growth hormone in the colon that helps damage DNA, which aides in the aging process. The finding could lead to new therapeutic approaches to aging-associated disorders like cancer. read more By Angus Liu As the Centers for Medicare & Medicaid Services is expected to make a coverage decision on Biogen’s controversial Alzheimer’s drug Aduhelm, the biotech is making an unexpected goodwill gesture—and an expected restructuring—as it faces pressure from all fronts. read more By Heather Landi Mental health startup Cerebral has inked a partnership with Alto Neuroscience to bring clinical trials for depression to patients’ homes. Through the collaboration, Cerebral is able to offer its network of members the opportunity to participate in at-home clinical research utilizing Alto’s biomarker platform and targeted drug candidates. read more By Conor Hale The FDA greenlighted U.K.-based Sky Medical's wearable electrical muscle stimulator to help stave off some of the symptoms of chronically blocked vessels such as varicose veins and blood pooling in the legs. The geko device, about the size of a wristwatch, stimulates a central nerve located at the top of the shin to increase circulation. read more By Angus Liu Bluebird bio simply can’t catch a break. Just half a year after coming off an FDA clinical hold, development of the biotech’s blood disease gene therapy LentiGlobin has once again been halted, this time in sickle cell disease patients under the age of 18. read more Resources Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored by: BBK Worldwide New survey results and insights help clinical trial sponsors improve diversity and inclusion, enroll faster, and keep participants engaged longer. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. | 
